Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
Publication date
2021-04-12
Authors
Wensink, G. Emerens
Elias, Sjoerd
Mullenders, Jasper
Koopman, Miriam
Boj, Sylvia F
Kranenburg, Onno
Roodhart, Jeanine
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.
Keywords
Oncology, Cancer Research, Review, Journal Article
Citation
Wensink, G E, Elias, S G, Mullenders, J, Koopman, M, Boj, S F, Kranenburg, O W & Roodhart, J M L 2021, 'Patient-derived organoids as a predictive biomarker for treatment response in cancer patients', NPJ precision oncology, vol. 5, no. 1, 30. https://doi.org/10.1038/s41698-021-00168-1